These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 37488541)

  • 21. Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.
    Mauas R; Urueña A; Cecchini D; Strada ML; Arietti S; Cassetti I; Nogueira NF; Salazar AS; Rodriguez VJ; Jones DL; Alcaide ML
    AIDS; 2023 May; 37(6):941-946. PubMed ID: 36728228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
    BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of AstraZeneca and sinopharm vaccines as boosters in protection against COVID-19 infection.
    Letafati A; Eyvazzadeh N; Gharehkhani A; Khorshidian A; Chalabiani S; Soufiani EK; Khakpoor N; Shamsodini B; Beheshti T; Bavili Olyaei RT; Soleimani A; Melyani F; Hossein GM
    Biologicals; 2023 May; 82():101668. PubMed ID: 37004277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy.
    Darweesh O; Khatab N; Kheder R; Mohammed T; Faraj T; Ali S; Ameen M; Kamal-Aldin A; Alswes M; Al-Jomah N
    PLoS One; 2022; 17(11):e0274526. PubMed ID: 36399454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study.
    Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M
    Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombotic events following Covid-19 vaccines compared to Influenza vaccines.
    Vallone MG; Falcón AL; Castro HM; Ferraris A; Cantarella RF; Staneloni MI; Aliperti VI; Ferloni A; Mezzarobba D; Vázquez FJ; Ratti MFG
    Eur J Intern Med; 2022 May; 99():82-88. PubMed ID: 35288031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
    Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Antibody Levels Produced by Pfizer, AstraZeneca, and Sinopharm Vaccination in COVID-19 Patients in Erbil City-Iraq.
    Majed SO
    Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):103-112. PubMed ID: 37300682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are some COVID-19 vaccines better than others regarding the short-term side effects?
    Al-Zidan R; Darweesh O; Salah M; Bebane P; Ahmed H; Abdulrazzaq G; Shanshal S; Alomari N
    Ceska Slov Farm; 2023; 72(1):45-54. PubMed ID: 36858979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran.
    Nabizadeh E; Honarmandpour F; Mashhadizade R; Honarmandpour A
    Clin Pathol; 2023; 16():2632010X231166798. PubMed ID: 37155553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of side effects of the dose-1 of AstraZeneca and Sinopharm vaccines in patients with multiple sclerosis in Kermanshah, Iran (2021).
    Razazian N; Sahraian MA; Rezaei M; Eskandarieh S; Khamoushian K; Mousavi SE; Fakhri N
    Curr J Neurol; 2023 Jan; 22(1):8-15. PubMed ID: 38011394
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study.
    Omeish H; Najadat A; Al-Azzam S; Tarabin N; Abu Hameed A; Al-Gallab N; Abbas H; Rababah L; Rabadi M; Karasneh R; Aldeyab MA
    Hum Vaccin Immunother; 2022 Dec; 18(1):1981086. PubMed ID: 34614383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca.
    Boshra MS; Hussein RRS; Mohsen M; Elberry AA; Altyar AE; Tammam M; Sarhan RM
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of COVID-19 vaccines.
    Al Khames Aga QA; Alkhaffaf WH; Hatem TH; Nassir KF; Batineh Y; Dahham AT; Shaban D; Al Khames Aga LA; Agha MYR; Traqchi M
    J Med Virol; 2021 Dec; 93(12):6588-6594. PubMed ID: 34270094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
    Jaber HM; Ebdah S; Al Haj Mahmoud SA; Abu-Qatouseh L; Jaber YH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2333104. PubMed ID: 38584118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.
    Zare H; Rezapour H; Mahmoodzadeh S; Fereidouni M
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108351. PubMed ID: 34801416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.